Sign Up
OverviewAPI
Eli Lilly acquires cancer therapy firm Point Biopharma for $1.4 billion, expanding into radiopharmaceutical treatments for cancer. The acquisition aims to address the challenges of modern cancer treatments, including expensive production and a short shelf life. Lilly expects the deal to close by the end of 2023.

Ask a question